BC
NBIX icon

Brinker Capital’s Neurocrine Biosciences NBIX Stock Holding History

Brinker Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$1.9M Sell
15,577
-74
-0.5% -$8.18K 0.06% 312
2020
Q1 		$1.35M Buy
15,651
+3,456
+28% +$338K 0.05% 333
2019
Q4 		$1.31M Buy
12,195
+89
+0.7% +$9.32K 0.04% 419
2019
Q3 		$1.09M Buy
12,106
+1,703
+16% +$159K 0.04% 459
2019
Q2 		$878K Buy
10,403
+51
+0.5% +$4.19K 0.03% 521
2019
Q1 		$912K Buy
10,352
+483
+5% +$40.4K 0.03% 492
2018
Q4 		$705K Buy
+9,869
New +$946K 0.03% 506

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return